Jafron Biomedical Co.,Ltd.
SZSE:300529.SZ
20.36 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,922.348 | 2,491.439 | 2,675.454 | 1,950.78 | 1,431.819 | 1,016.509 | 718.491 | 543.641 | 508.905 | 370.938 | 303.588 | 250.621 | 194.983 |
| Cost of Revenue
| 383.984 | 440.106 | 402.064 | 287.961 | 197.395 | 154.44 | 113.928 | 87.341 | 78.625 | 56.68 | 49.48 | 43.862 | 34.511 |
| Gross Profit
| 1,538.364 | 2,051.333 | 2,273.39 | 1,662.819 | 1,234.424 | 862.069 | 604.563 | 456.299 | 430.281 | 314.258 | 254.107 | 206.758 | 160.471 |
| Gross Profit Ratio
| 0.8 | 0.823 | 0.85 | 0.852 | 0.862 | 0.848 | 0.841 | 0.839 | 0.846 | 0.847 | 0.837 | 0.825 | 0.823 |
| Reseach & Development Expenses
| 245.379 | 253.908 | 173.771 | 80.759 | 68.452 | 46.138 | 26.63 | 21.772 | 17.39 | 15.131 | 9.839 | 12.82 | 0 |
| General & Administrative Expenses
| 48.449 | 32.359 | 31.148 | 25.273 | 28.121 | 22.885 | 16.234 | 16.23 | 13.178 | 9.167 | 6.967 | 32.598 | 25.256 |
| Selling & Marketing Expenses
| 615.974 | 700.633 | 598.488 | 468.438 | 425.886 | 299.345 | 209.66 | 150.489 | 137.174 | 93.562 | 75.284 | 61.547 | 49.38 |
| SG&A
| 664.423 | 732.993 | 629.637 | 493.71 | 454.007 | 322.23 | 225.894 | 166.72 | 150.352 | 102.729 | 82.251 | 94.145 | 74.636 |
| Other Expenses
| -22.799 | 59.617 | 87.686 | 74.415 | 73.882 | -3.171 | 8.428 | 8.887 | 7.815 | 17.246 | 6.882 | 7.583 | 4.633 |
| Operating Expenses
| 1,015.207 | 1,046.519 | 891.094 | 648.884 | 596.341 | 428.043 | 310.222 | 229.088 | 202.465 | 143.647 | 113.508 | 98.563 | 78.107 |
| Operating Income
| 543.819 | 1,029.455 | 1,417.924 | 1,054.352 | 680.33 | 476.308 | 331.71 | 233.769 | 232.04 | 174.044 | 145.099 | 112.93 | 86.241 |
| Operating Income Ratio
| 0.283 | 0.413 | 0.53 | 0.54 | 0.475 | 0.469 | 0.462 | 0.43 | 0.456 | 0.469 | 0.478 | 0.451 | 0.442 |
| Total Other Income Expenses Net
| -22.799 | -12.647 | -10.707 | -22.404 | -9.048 | 39.111 | 45.797 | 14.248 | 12.007 | 20.504 | 11.312 | 12.28 | 8.489 |
| Income Before Tax
| 521.02 | 1,016.808 | 1,407.218 | 1,031.948 | 671.282 | 473.137 | 340.138 | 241.459 | 239.823 | 191.115 | 151.911 | 120.475 | 90.853 |
| Income Before Tax Ratio
| 0.271 | 0.408 | 0.526 | 0.529 | 0.469 | 0.465 | 0.473 | 0.444 | 0.471 | 0.515 | 0.5 | 0.481 | 0.466 |
| Income Tax Expense
| 95.297 | 135.89 | 211.376 | 158.952 | 102.589 | 72.191 | 55.686 | 39.341 | 39.382 | 31.066 | 25.127 | 20.451 | 15.091 |
| Net Income
| 436.492 | 889.564 | 1,196.813 | 875.241 | 570.823 | 401.98 | 284.414 | 202.118 | 200.441 | 160.048 | 126.785 | 100.024 | 75.762 |
| Net Income Ratio
| 0.227 | 0.357 | 0.447 | 0.449 | 0.399 | 0.395 | 0.396 | 0.372 | 0.394 | 0.431 | 0.418 | 0.399 | 0.389 |
| EPS
| 0.55 | 1.12 | 1.49 | 1.1 | 0.72 | 0.51 | 0.36 | 0.27 | 0.28 | 0.23 | 0.18 | 0.14 | 0.31 |
| EPS Diluted
| 0.55 | 1.12 | 1.49 | 1.08 | 0.72 | 0.51 | 0.36 | 0.27 | 0.28 | 0.23 | 0.18 | 0.14 | 0.31 |
| EBITDA
| 683.379 | 1,130.551 | 1,475.701 | 1,052.595 | 702.929 | 496.55 | 310.616 | 258.703 | 238.01 | 175.894 | 143.567 | 110.959 | 83.955 |
| EBITDA Ratio
| 0.355 | 0.454 | 0.552 | 0.54 | 0.491 | 0.488 | 0.432 | 0.476 | 0.468 | 0.474 | 0.473 | 0.443 | 0.431 |